The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

“…When they stop being introduced in further assembly events (i.e. introduced species do not carry any mutualistic interactions), their proportion slowly decreases with successive invasions. …”

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

CM-DWM-EC chart using 30% decrease in the mean for the E(KeV). by Shumaila Nisar (20114256)

“…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

FBP primarily decreases the protein level of HMGB1 by promoting its lysosomal degradation upon viral infection. by Penghui Hu (695020)

Dox-inducible expression of HA-MAD1 in colon is sufficient to decrease p53 expression and cause chromosome missegregation. by Sarah E. Copeland (13951506)

“…Lanes 2 and 3 are from different mice of the same genotype. (E) Quantification (mean +/- SEM) of p53 protein levels, based on immunoblotting with the 1C12 antibody. …”

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects: